Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Inogen, Spectrum Brands, Bridgepoint, and Corbus and Encourages Investors to Contact the Firm
28 mars 2019 20h00 HE
|
Bragar Eagel & Squire
NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Inogen, Inc., and Spectrum...
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Corbus Pharmaceuticals Holdings, Inc. (CRBP) and Encourages CRBP Investors to Contact the Firm
12 mars 2019 21h10 HE
|
Bragar Eagel & Squire
NEW YORK, March 12, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on...
Corbus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Clinical Updates
12 mars 2019 07h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
●Pipeline of rationally-designed synthetic cannabinoids position Corbus to become the leader in treating inflammatory and fibrotic diseases by targeting the endocannabinoid system (ECS)...
Corbus Pharmaceuticals to Announce Full-Year 2018 Operational and Financial Results on March 12, 2019
07 mars 2019 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
- Company to host conference call and webcast on Tuesday, March 12 at 8:30 a.m. ET - Norwood, MA, March 07, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”...
Corbus Pharmaceuticals Announces Appointment of Craig Millian as Chief Commercial Officer
04 mars 2019 09h15 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Advances commercialization strategy for lenabasum ahead of data readouts of key registrational studies in 2020, and potential U.S. Food and Drug Administration (“FDA”) approval and launch in 2021Mr....
Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock
24 janv. 2019 16h01 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company with the industry’s...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in November
06 nov. 2018 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
– Jefferies 2018 London Healthcare Conference presentation with live audio webcast on Thursday, November 15 at 4:40 p.m. GMT – – 30th Annual Piper Jaffray Healthcare Conference presentation with...
Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study
20 sept. 2018 07h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Management to host conference call and webcast this morning at 8:30 a.m. EDTJenrin’s extensive pipeline positions Corbus to be a leader in the treatment of inflammatory and fibrotic diseases with...
Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2018 ACR Annual Meeting
14 sept. 2018 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presented Norwood, MA, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings,...
Corbus Pharmaceuticals to Present at the Annual B. Riley FBR Healthcare Conference
23 août 2018 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a Phase 3 clinical-stage pharmaceutical company focused on the...